Lonza reached a deal to sell its capsule and health ingredients unit to a UK‑based investment firm for $2.2 billion upfront as part of a portfolio simplification move. The sale follows long‑running strategic reviews and will allow Lonza to narrow focus on higher‑margin biologics and cell‑gene therapy manufacturing. Proceeds will support the company’s operational priorities and potential reinvestment in core biotech services. The transaction highlights continued M&A activity in life‑science supply chains where specialized manufacturing assets command strategic premiums.